Avestha Long Term Growth PMS Review: Performance, Fees & Should You Stay Invested?

Quick Summary

What Works	What Doesn’t
Positive alpha over the S&P BSE 500 TRI across the 2, 3, 5-year, and since-inception periods	Sharply negative 1-year alpha (-3.76%) and a negative Sharpe Ratio (-0.64) — the most recent, most relevant window looks weak
Highly experienced fund manager (Farokh Pandole — Harvard, Wharton, Alliance Capital, Citigroup, BofA-Merrill Lynch, HDFC Life) with continuous tenure since inception	Labeled “Multi Cap & Flexi Cap,” but 78.84% of the portfolio sits in mid and small caps — just 16.28% is large cap
Sector-level portfolio disclosure and zero exit load in all years	Heavy single-sector concentration — Defense alone is 24.60% of the portfolio, with the top 5 sectors at 66.63%
Comparatively investor-friendly headline fee (1.00% fixed AMC fee, or 5% profit share above a high watermark)	The eye-catching 15.90% since-inception return is anchored substantially by one outsized year (CY21: +52.63%) a new investor today cannot access

Verdict: Avestha Long Term Growth has a genuinely strong long-run track record and a capable, well-credentialed manager — but the portfolio you’d be buying into today looks very different from what the “Multi Cap & Flexi Cap” label suggests, and the most recent 12 months show real cracks in both return and risk-adjusted performance. Whether the historical edge is still intact being exactly the question this review works through.

The PMS Value Framework

Gross Alpha > Fee = Value Added | Gross Alpha ≈ Fee = Break-Even | Gross Alpha < Fee = Value Destroyed

Since inception, this strategy’s alpha over its benchmark (+3.59%, using the disclosed 15.90% vs 12.31% S&P BSE 500 TRI figures) has comfortably exceeded its modest fee load — placing it, on paper, in the value-added zone.

That’s a fair, data-backed statement, and we’re not going to take it away from the fund.

But that verdict rests almost entirely on a track record anchored by one extraordinary year. Strip out the framing of “since inception” and look instead at where the strategy is right now — a -3.83% one-year return against a -0.07% benchmark, and a negative Sharpe Ratio — and the picture shifts toward the break-even-to-value-destroyed zone.

Both statements are true. Which one matters more depends on what you’re actually paying for: a legacy number, or what the portfolio looks like today.

Table of Contents

1. Who Should Read This

2. Who This PMS May Still Suit

3. Who Should Likely Avoid This PMS

4. What Is Avestha Long Term Growth?

5. Performance Review

6. The Fee Reality

7. The Zero-Based Thinking Test

8. Decision Factor Scorecard

9. The Core Portfolio Architecture Question

10. What a Genuinely Complementary PMS Looks Like

11. Exit Considerations

12. Key Takeaways

13. FAQ

14. Our Approach

1. Who Should Read This

• You’re currently invested in Avestha Long Term Growth and want an honest read on whether the portfolio still matches what you signed up for
• You’re evaluating this PMS against your existing mutual fund holdings before committing ₹2 Crore
• You want to understand what “Multi Cap & Flexi Cap” actually means in practice — versus what it says on the label
• You’re trying to separate a fund’s headline since-inception number from what it’s actually delivering right now
• You’re building a core-satellite portfolio and want to know if a concentrated, sector-heavy strategy like this belongs in it

2. Who This PMS May Still Suit

• Investors who specifically want a concentrated, high-conviction small-and-midcap satellite bet, and understand that’s what they’re buying — not a diversified multi-cap holding
• Investors comfortable with meaningful single-sector exposure, including a near-25% weight to Defense, and who’ve done independent diligence on that concentration
• Investors with a genuinely long horizon (7-10 years+), the full ₹2 Crore available as a lump sum, and the temperament to sit through a year like CY18 or the current one without reacting
• Investors who value manager pedigree and continuity — Farokh Pandole has run this exact strategy, uninterrupted, since November 2017

3. Who Should Likely Avoid This PMS

• Investors expecting genuine multi-cap diversification; the disclosed composition (78.84% mid + small cap) doesn’t match that expectation
• Investors anchoring their decision to the 15.90% since-inception headline without accounting for how much of it came from a single year (CY21: +52.63%)
• Investors who need SIP or STP entry — neither is available here, meaning the full ₹2 Crore has to go in at once, with all the timing risk that implies
• Risk-averse investors; a negative 1-year Sharpe Ratio and 21.75% standard deviation indicate the recent ride has been rough relative to the reward

4. What Is Avestha Long Term Growth?

Key Fact	Detail
AMC	Avestha Fund Management LLP
Strategy	Long Term Growth
Category	PMS – Multi Cap & Flexi Cap
Benchmark	S&P BSE 500 TRI
Inception Date	1 November 2017
Portfolio Age	~8 Years, 6-8 Months (as on 31 May 2026)
Minimum Investment	₹2,00,00,000
AUM	₹1,430.36 Cr
Stocks in Portfolio	16
Fund Manager	Mr. Farokh Pandole (Founder & Portfolio Manager)
SIP / STP	Not Available

Here’s the mandate, in the AMC’s own words: a concentrated portfolio of 12-18 holdings, run buy-and-hold, with stock selection described as “sector agnostic” and bottom-up — built around balance sheet strength, promoter history, capital efficiency, and growth runway.

Now here’s the reality check. “Sector agnostic” is the stated process.

The outcome is a portfolio where the top 5 sectors account for 66.63% of holdings, with Defense alone at 24.60%.

That’s not necessarily a broken process — concentrated, bottom-up stock-picking can genuinely land you in a handful of sectors without anyone setting out to make a sector call.

But you should know that’s what you’re holding: a concentrated sector bet, whether or not it was built that way on purpose.

Farokh Pandole’s background is substantial: Honours in Economics from Harvard College, an MBA in Finance from Wharton, a stint managing $250mn in FII/MF assets at Alliance Capital Mutual Fund, sell-side leadership roles at Citigroup and Bank of America-Merrill Lynch, and most recently an equity portfolio manager role at HDFC Life.

Continuity risk is low — he’s run this exact strategy since it launched in November 2017.

5. Performance Review

Trailing Returns Vs Benchmark (as on 31 May 2026)

Period	Avestha Long Term Growth	S&P BSE 500 TRI	Alpha (+/-)
1 Month	1.39%	-0.17%	+1.56%
3 Month	9.19%	-2.34%	+11.53%
6 Month	-0.24%	-5.39%	+5.15%
1 Year	-3.83%	-0.07%	-3.76%
2 Year	10.18%	4.14%	+6.04%
3 Year	14.35%	13.46%	+0.89%
5 Year	18.75%	12.29%	+6.46%
Since Inception	15.90%	12.31%	+3.59%

Calendar Year Returns (Avestha Long Term Growth)

CY17	CY18	CY19	CY20	CY21	CY22	CY23	CY24	CY25	CY26 YTD
3.90%	~-6%*	10.95%	13.37%	52.63%	13.91%	33.19%	27.61%	-1.73%	4.93%

*CY18 figure was partially illegible in the source disclosure; direction and approximate magnitude shown, exact decimal not confirmed.

Here’s the thing about a since-inception number: it treats every year the same, no matter how unusual it was.

CY21 was unusual — a 52.63% return, more than three times the strategy’s next-best year.

Strip that single year out, and the long-run story looks more ordinary: solid but unspectacular years in CY19, CY20, CY22 (11-14% range), a strong CY23-24, then a reversal into CY25 (-1.73%) and a weak trailing 12 months (-3.83%, against a benchmark that itself fell only -0.07%).

That reversal deserves attention. The 2, 3, and 5-year alpha numbers are genuinely positive — real credit is due.

But the most recent 12 months tell a different story: a fund not just underperforming its benchmark, but losing money in absolute terms while its benchmark was roughly flat.

Conclusion on the pattern: This isn’t a structurally broken strategy. It’s a concentrated, sector-tilted portfolio that rode a strong multi-year run — including one outsized year — and has hit a rough patch recently.

Whether that’s temporary or structural is genuinely unknowable from the data alone.

What is knowable is that the version of this fund a new investor buys today runs hot-and-cold in ways the smooth since-inception number doesn’t show.

6. The Fee Reality

Fee Structure

Component	Fixed Fee Plan	Variable Fee Plan
AMC Fee	1.00%	No standalone option — profit share applies on top of the fixed fee
Hurdle Rate	—	0% (no hurdle)
Profit Sharing	—	5% of gains, with high watermark protection
Exit Load (Yr 1 / 2 / 3)	0.00% / 0.00% / 0.00%	0.00% / 0.00% / 0.00%

To Avestha’s credit, this is a genuinely lighter fee structure than many PMS peers — a 1% base fee and a modest 5% profit share, protected by a high watermark so you’re not charged twice for the same gain.

Here’s the one thing worth flagging: there’s no hurdle rate.

The profit share applies to any gain above the watermark, not just gains above a minimum bar like the 10% hurdles common elsewhere.

That’s a lower threshold for the manager to start earning performance fees, even in a year that merely tracks the market.

Fee Drag on ₹50 Lakhs: The Rupee Picture

Using the more representative 3-year trailing rate (rather than the CY21-skewed since-inception figure) as a forward-looking base case, against a passive index fund tracking the benchmark at a 0.15% fee:

Scenario	Return Assumed (p.a.)	Corpus After 5 Years	Corpus After 7 Years
Avestha Long Term Growth (Net, at 3-Year trailing rate)	14.35%	₹97,75,767	₹1,27,82,717
Passive Index Fund tracking S&P BSE 500 TRI (Net of 0.15% fee)	13.31%	₹93,39,233	₹1,19,90,787
The Gap	—	₹4,36,534	₹7,91,931

On this more grounded, recent-performance basis, the PMS still edges ahead — by roughly ₹4.4 lakh over 5 years and ₹7.9 lakh over 7 years on a ₹50 lakh corpus.

That’s a real, defensible edge, and meaningfully smaller than what the since-inception headline number would suggest if you extrapolated it forward.

Here’s the question that matters more than the table: which rate should you actually expect going forward — the 14.35% blended 3-year rate, or the -3.83% you’re living through right now? You don’t get to pick.

The next twelve months will look like one, the other, or something in between — and no fee structure, however investor-friendly, protects you from that uncertainty.

7. The Zero-Based Thinking Test

Here’s the only question that matters: knowing everything you now know, if you had ₹2 Crore sitting uninvested today, would you put it into this exact 16-stock portfolio — 78.84% in mid and small caps, nearly a quarter of it in Defense — based on a since-inception number substantially built by one exceptional year in 2021?

Not “should I stay because I’ve already committed.” Not “should I stay because the manager has a great résumé.” Just — would you sign up for this today, with the portfolio as it actually stands?

You might be asking yourself: doesn’t the long track record count for something? It counts for returns already banked. It doesn’t obligate you to keep collecting future returns from the same vehicle if the case looks different today than it did in 2017 or 2021. The money doesn’t know how long it’s been there. It only cares where it goes next.

So flip the framing. Staying invested is a decision, not a default — and deserves the same scrutiny as a fresh one. If the fund’s current risk profile (negative Sharpe, 21.75% volatility, a 24.6% single-sector bet) wouldn’t get you to write a cheque today, that discomfort is telling you something real.

To be fair to your original decision: 2017-2021 rewarded concentrated, cap-flexible stock-pickers handsomely, and this manager delivered. The question now is different, with different information. Would you make the same call today, looking at the portfolio as it actually stands?

8. Decision Factor Scorecard

Decision Factor	Rating	Analysis
Uniqueness vs. existing MF portfolio	🟡	Sector disclosure (Defense, Auto, Metals, Manufacturing, Healthcare Services) shows real differentiation from a typical MF blend. But top-5 stock-level holdings remain undisclosed, so true overlap can’t be fully verified.
Alpha consistency across all periods	🟡	Positive alpha at 2, 3, 5-year, and since-inception horizons. But 1-year alpha is sharply negative (-3.76%), and a negative Sharpe Ratio confirms the recent period underperformed on a risk-adjusted basis too.
Justification for PMS premium fee	🟡	The 1% + 5% (high-watermark, no hurdle) fee is lighter than most PMS peers and has been justified over the fund’s life. The absence of a hurdle, though, means performance fees apply on any gain — a lower bar than hurdle-based peers.
Downside protection in market corrections	🔴	A negative 1-year Sharpe Ratio (-0.64) and 21.75% standard deviation show risk hasn’t translated into reward recently. CY18 and CY25 were both negative, and the current 12-month window is negative in absolute terms.
Portfolio complement for MF investor	🟡	The small/midcap and Defense tilt could genuinely complement a large-cap-heavy core — a legitimate case. But with only 16 stocks and 66.63% in five sectors, it reads more as a concentrated satellite bet than a broad complement.
Mandate purity and discipline	🔴	Labeled “Multi Cap & Flexi Cap,” but disclosed composition shows 78.84% in mid and small caps against just 16.28% large cap. In practice, this behaves like a concentrated small/midcap strategy.
Fund manager transparency	🟢	Farokh Pandole’s career is thoroughly disclosed — Harvard, Wharton, Alliance Capital, Citigroup, BofA-Merrill Lynch, HDFC Life. Sector-level disclosure is also provided, a step up versus many PMS peers.
Investment horizon suitability	🟡	The “Long Term Wealth Creation” buy-and-hold philosophy matches the fund’s 8-plus year record. But no SIP or STP means the full ₹2 Crore goes in as a lump sum, adding entry-timing risk.
Market cap flexibility utilisation	🔴	The mandate allows cap flexibility, but current allocation (49.79% small cap, 29.05% mid-cap, 16.28% large cap) shows that flexibility used almost entirely in one direction.
Concentration vs. diversification balance	🔴	16 stocks, with the top 5 sectors at 66.63% and Defense alone at 24.60%. A genuinely concentrated, high-conviction portfolio — suited only to investors who fully accept single-sector risk at this scale.
AUM size and strategy capacity	🟡	₹1,430.36 Cr isn’t large in absolute terms, but with roughly half the book in small caps across just 16 positions, liquidity and capacity constraints are a legitimate concern in a stressed market.
Manager tenure and continuity risk	🟢	Farokh Pandole has run this strategy continuously since November 2017 — over eight years on the same mandate, with no evidence of transition. Continuity risk is low.
Style consistency vs. stated mandate (strategy-specific)	🔴	The stated approach is “sector agnostic” and “multi cap.” The disclosed portfolio is concentrated in mid/small caps and heavily weighted to Defense. This gap is the single biggest thing worth questioning here.

Summary Scorecard

Decision Factor	Rating
Uniqueness vs. existing MF portfolio	🟡
Alpha consistency across all periods	🟡
Justification for PMS premium fee	🟡
Downside protection in market corrections	🔴
Portfolio complement for MF investor	🟡
Mandate purity and discipline	🔴
Fund manager transparency	🟢
Investment horizon suitability	🟡
Market cap flexibility utilisation	🔴
Concentration vs. diversification balance	🔴
AUM size and strategy capacity	🟡
Manager tenure and continuity risk	🟢
Style consistency vs. stated mandate	🔴

9. The Core Portfolio Architecture Question

Your core should be the part of your portfolio you don’t have to think about — low-cost, diversified, built from index funds, flexi-cap funds, or multi-asset funds giving broad market exposure at minimal cost.

Your satellite is where you take selective, higher-conviction bets — PMS and AIF strategies that earn their place by doing something your core structurally cannot: a concentrated small-cap opportunity set, a genuine sector tilt, positions a diversification-mandated mutual fund would never take.

On paper, a concentrated, Defense-and-small-cap-tilted strategy like this could be a textbook satellite holding — it’s clearly not duplicating a typical large-cap-anchored core.

The real question isn’t whether it’s differentiated. It’s whether you understood, going in, that “Multi Cap & Flexi Cap” would mean a 78.84% mid-and-small-cap, single-sector-concentrated book — and whether that’s the specific risk you intended to take with ₹2 Crore.

10. What a Genuinely Complementary PMS Looks Like

If you’re evaluating any PMS for your satellite sleeve — this one or another — look for:

• Disclosed, verifiable holdings you can cross-check against your existing mutual fund portfolio for overlap
• A category label that matches the actual portfolio — if it’s concentrated and cap-tilted, it should be described that way, not filed under a broader “multi-cap” banner
• Alpha that holds up across full market cycles, including the most recent one, not just a track record propped up by a single standout year
• Risk-adjusted metrics you can actually see — Sharpe Ratio, standard deviation, drawdown behaviour — not just headline returns
• A fund manager willing to explain, in writing, why the current concentration exists and what would change it

11. Exit Considerations

The good news: exit load is 0.00% in year 1, year 2, and year 3. There’s no financial penalty structure standing between you and a decision to leave.

As with any PMS, tax treatment differs from a mutual fund. Your holdings sit directly in your own Demat account, so every buy and sell the manager executes is a taxable event in your hands — stock-level LTCG or STCG, not fund-level capital gains recognized only on your own redemption.

One-point specific to this portfolio: with only 16 stocks and roughly half the book in small caps, a single large redemption could face real market-impact costs if you try to exit all at once.

A staggered exit — spread across weeks or a financial year — isn’t just a tax-planning tool here; it’s a practical necessity given the portfolio’s liquidity profile.

There’s no exit-load clock forcing your hand, so there’s no reason to rush a decision either way.

12. Key Takeaways

1. Avestha Long Term Growth shows genuinely positive alpha over the S&P BSE 500 TRI at the 2, 3, 5-year, and since-inception horizons.
2. The most recent 12 months are the exception — alpha is -3.76%, and the Sharpe Ratio is negative, indicating real risk hasn’t translated into reward lately.
3. The since-inception CAGR (15.90%) is substantially anchored by one outsized year (CY21: +52.63%) that a new investor cannot access going forward.
4. Despite its “Multi Cap & Flexi Cap” label, the portfolio is 78.84% concentrated in mid and small caps, with Defense alone at 24.60%.
5. The fee structure (1% fixed, 5% profit share with high watermark, no hurdle) is comparatively investor-friendly, but the lack of a hurdle lowers the bar for performance fees.
6. Exit load is nil across all years; tax and liquidity, not penalties, are the real considerations on exit.
7. Fund manager continuity is strong — Farokh Pandole has run this strategy since inception with a well-documented, credible career.
8. Top-5 stock-level holdings remain undisclosed, limiting full verification of overlap with your existing mutual fund portfolio.

13. FAQ

i. Is Avestha Long Term Growth a good or bad PMS?

It has a genuinely strong long-run alpha record, heavily influenced by one outsized year, and the most recent 12 months show clear underperformance and weak risk-adjusted returns. The honest answer depends on which period you weight.

ii. What are Avestha Long Term Growth’s returns?

As on 31 May 2026: -3.83% (1-year), 10.18% (2-year), 14.35% (3-year), 18.75% (5-year), and 15.90% since inception (1 November 2017).

iii. What is the Avestha PMS fee structure?

A 1.00% fixed AMC fee, plus a 5% profit share on gains above a high watermark (no hurdle rate). Exit load is nil in all years.

iv. What is Avestha Fund Management’s AUM and minimum investment? AUM of Avestha Fund Management PMS is ₹1,430.36 Cr as on 31 May 2026; minimum investment is ₹2,00,00,000.

v. Who manages the Avestha Long Term Growth PMS?

Mr. Farokh Pandole, Founder and Portfolio Manager, who has run the Avestha Long Term Growth PMS strategy continuously since its November 2017 inception.

vi. Is this really a multi-cap PMS?

By label, yes. By disclosed composition, it holds 78.84% in mid and small caps and only 16.28% in large caps — behaving more like a concentrated small/midcap strategy.

vii. PMS vs mutual fund India — is a concentrated PMS like this worth the fee?

For a genuinely differentiated, concentrated strategy, a premium fee can be justified if the alpha holds up across cycles. The test is whether recent performance still supports that case, not just the historical average.

viii. Are PMS fees worth it here?

The fee itself is relatively investor-friendly. Whether it’s “worth it” depends on whether the fund’s historical edge — heavily shaped by one strong year — repeats, given the current negative-alpha, Negative-Sharpe environment.

ix. How do I exit a PMS like this one?

Holdings sit in your own Demat account, so exiting triggers stock-level capital gains tax. Given the concentration in less-liquid small caps, a staggered exit over several weeks or a financial year is advisable, both for tax planning and market-impact costs.

x. What does underperformance mean if the since-inception number still looks strong?

It means an average can hide a lot. A fund can show a strong since-inception CAGR built substantially on one outstanding year, while its recent trailing periods tell a far less flattering story — close to the pattern here.

14. Our Approach

We’re a process-driven wealth advisory built around a core-satellite philosophy: a low-cost, diversified core, and a satellite sleeve reserved for strategies that genuinely complement it.

On the data currently disclosed, Avestha Long Term Growth doesn’t clear our bar for recommendation right now — not because the manager lacks credibility, but because the portfolio’s current composition, concentration, and recent risk-adjusted performance don’t match the comfort a “Multi Cap & Flexi Cap” label implies.

If you’re already invested here, we’re happy to review this PMS alongside your existing mutual fund portfolio — as your CFP, not as a product seller — to check whether the concentration and sector exposure genuinely complement what you hold elsewhere, and help you think through what, if anything, should change.